Recent Posts
Anaveon doses first patient in a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumorsJune 24, 2021
Anaveon receives CTA approval to start a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumorsMarch 25, 2021
Anaveon announces presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 10, 2020